ArticleJournal of inflammation research2026
Hemoglobin-to-Inflammation Marker Ratios Reflect Endoscopic Activity in Inflammatory Bowel Disease.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To investigate the diagnostic value of hemoglobin-to-inflammation marker ratios (Hb/WBC, Hb/Neu, Hb/PLT, Hb/CRP) in assessing endoscopic activity in inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD). Methods: A single-center retrospective cross-sectional study was conducted. We screened patients diagnosed with UC or CD between January 2017 and July 2025. Patients were excluded if they had coexisting severe gastrointestinal/infectious diseases potentially affecting endoscopic or laboratory results, iron supplements intake, incomplete data, or a significant time discrepancy (>3 days) between endoscopy and laboratory testing. Ultimately, 270 IBD patients (175 UC, 95 CD) were included for the primary cross-sectional analysis. Clinical data, laboratory indicators, and endoscopic scores (Mayo Endoscopic Score, Ulcerative Colitis Endoscopic Index of Severity [UCEIS], Simplified Endoscopic Score for Crohn's Disease [SES-CD]) were collected. Receiver operating characteristic (ROC) curve analysis, correlation analysis, multivariate logistic regression, and sensitivity analyses were employed. Results: The Hb/CRP ratio demonstrated the best performance in distinguishing endoscopic active phase from remission phase in IBD. In UC patients based on the Mayo Endoscopic Score, the area under the curve (AUC) of Hb/CRP was 0.924 (95% CI: 0.884-0.964); based on the UCEIS score, the AUC was 0.890 (95% CI: 0.842-0.938); in CD patients based on the SES-CD score, the AUC was 0.839 (95% CI: 0.749-0.929). Hb/CRP significantly outperformed hemoglobin alone across all subgroups (all P<0.01), while showing comparable diagnostic accuracy to CRP alone. It also served as an independent protective factor for disease remission phase in multivariate analysis (odds ratio [OR] range = 1.007 to 1.014, all P<0.01). Sensitivity analyses stratified by anemia status confirmed the robustness of Hb/CRP, particularly in UC patients. However, the absence of fecal calprotectin (FC) data is a key limitation of the study. Conclusion: Hemoglobin-to-inflammation ratios, particularly Hb/CRP, show promising diagnostic performance for assessing endoscopic activity in IBD in this retrospective study. They may serve as non-invasive adjunctive tools for clinical disease activity monitoring, though their comparative value against established biomarkers like FC warrants further prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.